Reinvigorating the Cancer‐Immunity Cycle With Combined Oncolytic Virus and CAR‐T Cell Therapies in Solid Tumors
Pathology International · 2026
DOI: 10.1111/pin.70117 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology International, 2026. Verfasst von Keisuke Watanabe und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Immunology, Research Institute, National Cancer Center Japan, Tokyo, Japan. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive, Oncolytic Virotherapy, Receptors, Chimeric Antigen. Die Arbeit nennt 84 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology of Japan, Project for Advanced Drug Discovery and Development from the Japan Agency for Medical Research and Development (AMED), National Cancer Center Research and Development.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)‐T‐cell therapies have shown remarkable clinical efficacy in hematological malignancies. However, objective clinical responses in solid tumors are limited. Various obstacles, such as the lack of ideal tumor‐specific antigens and the immunosuppressive tumor microenvironment (TME), which impairs multiple immunological steps required to achieve effective cancer control, compromise the antitumor efficacy of CAR‐T‐cell therapy in solid tumors. To address this issue, combination treatment with oncolytic viruses (OVs) and CAR‐T cells is being explored. OVs can modulate immunosuppression in the TME and invigorate both endogenous and adoptively transferred T cells, in addition to directly killing tumor cells. The immunomodulatory effect is further augmented by the use of OVs with therapeutic transgenes as payloads. Many preclinical evaluations have provided promising evidence for the combination approach, and clinical studies are ongoing. In this review, the mechanisms underlying resistance to CAR‐T‐cell therapies and recent advances in combination therapy with OVs and CAR‐T cells are discussed from the perspective of the cancer‐immunity cycle.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Immunology, Research Institute, National Cancer Center Japan, Tokyo, Japan.
- Division of Cancer Immune Multicellular System Regulation, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
ORCID-Profile: Keisuke Watanabe
Förderung
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- Project for Advanced Drug Discovery and Development from the Japan Agency for Medical Research and Development (AMED)
- National Cancer Center Research and Development
Zitieren
APA
Watanabe, K., & Nishikawa, H. (2026). Reinvigorating the Cancer‐Immunity Cycle With Combined Oncolytic Virus and CAR‐T Cell Therapies in Solid Tumors. Pathology International. https://doi.org/10.1111/pin.70117
Vancouver
Watanabe K, Nishikawa H. Reinvigorating the Cancer‐Immunity Cycle With Combined Oncolytic Virus and CAR‐T Cell Therapies in Solid Tumors. Pathology International. 2026. doi:10.1111/pin.70117
BibTeX
@article{Watanabe2026,
author = {Watanabe, Keisuke and Nishikawa, Hiroyoshi},
title = {Reinvigorating the Cancer‐Immunity Cycle With Combined Oncolytic Virus and CAR‐T Cell Therapies in Solid Tumors},
journal = {Pathology International},
year = {2026},
doi = {10.1111/pin.70117}
}
EUVIMED